Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Colorcon
AstraZeneca
Johnson and Johnson
Mallinckrodt
Baxter
McKesson

Last Updated: March 28, 2020

DrugPatentWatch Database Preview

Litigation Details for Teva Pharmaceuticals USA, Inc. v. Sandoz, Inc. (S.D.N.Y. 2008)


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

Teva Pharmaceuticals USA, Inc. v. Sandoz, Inc. (S.D.N.Y. 2008)

Docket   Start Trial Date Filed 2008-08-28
Court District Court, S.D. New York Date Terminated 2012-07-24
Cause 35:271 Patent Infringement Assigned To William H. Pauley III
Jury Demand Defendant Referred To Andrew J. Peck
Parties MOMENTA PHARMACEUTICALS, INC.; NATCO PHARMA LTD.; NOVARTIS AG; SANDOZ INC.; SANDOZ INTERNATIONAL GMBH; SANDOZ, INC.; TEVA NEUROSCIENCE, INC.; TEVA PHARMACEUTICAL INDUSTRIES LTD.; TEVA PHARMACEUTICALS USA, INC.; YEDA RESEARCH AND DEVELOPMENT CO. LTD.
Patents 5,981,589; 6,054,430; 6,342,476; 6,362,161; 6,620,847; 6,939,539; 7,199,098
Attorneys Anders T. Aannestad; Andrew Levine; Beth D. Jacob; Brian Jeffrey Eutermoser; Brian Matthew Kramer; Carolyn Anne Blessing; Daryl L Wiesen; David C. Doyle; David L. Anstaett; David M. Hashmall; Elizabeth J. Holland; Eric M. Acker; Grant Joseph Esposito; Jeffrey A. Simes; John T. Bennett; Jonathan Aaron Auerbach; Joseph B. Crystal; Karen Louise Hagberg; Matthew Mark D'Amore; Miriam London Martinez; Nicholas K Mitrokostas; Patrice Polyxene Jean; Patricia Young; Ricardo Solano , Jr; Richard B. Mills-Robertson; Sarah C. Walkenhorst; Stephen D Keane; Steven Jeffrey Lee; William G. James , II; William Mcginley Jay
Firms Friedman, Kaplan, Seiler and Adelman, LLP; Gibson, Dunn & Crutcher, LLP (DC); Goodwin Procter, LLP (Boston); Goodwin Procter, LLP (DC); Goodwin Procter, LLP (NYC), the New York Times Building; Morrison & Foerster LLP; Morrison & Foerster LLP (NYC); Morrison & Foerster, LLP -- San Diego; Morrison and Foerster; Perkins Coie LLP; Perkins Coie, L.L.P (WISC); Schiff Hardin LLP; Teva Pharamaceuticals USA, Inc.; Weil, Gotshal & Manges LLP (NYC)
Link to Docket External link to docket
Small Molecule Drugs cited in Teva Pharmaceuticals USA, Inc. v. Sandoz, Inc.
The small molecule drug covered by the patents cited in this case is   Start Trial .

Details for Teva Pharmaceuticals USA, Inc. v. Sandoz, Inc. (S.D.N.Y. 2008)

Date Filed Document No. Description Snippet Link To Document
2008-08-28 1 Complaint 5,800,808 A * 9/1998 Konfloo et al. 424/78.08 5,981,589 A "‘ ll/l999 Konfino et al, ......... 514…,409 A 6/1986 Hayashii et al. .. ..... 424/78 5,981,589 A * 11/1999 Kontino etal. 514/561 6,054,430 A …the ’098' patent 17. Unitcd'St`a`tes Patent No. 6_,939_,539 (“the; ’5_39 patent”), entitled “… of the ’430 patent 21. United=.States Patent N'o. 6_,62_0,__8_47 (“th_e ’847 patent”)_, entitled…United Stat€S Patent [19] [11] Patent Number: 6,054,430 Konlino et al. [45] Date of Patent: Apr. 25, 2000 External link to document
2011-08-29 194 Order on Motion for Summary Judgment nine patents are: 5,800,808 (“‘808 patent”), 5,981,589 (“‘589 patent”), 6,048,898 (“‘898 patent”), 6,…(“‘430 patent”), 6,342,476 (“‘476 patent”), 6,362,161 (“‘161 patent”), 6,620,847 (“‘847 patent”), 6,939,539…contends that the patent teaches that the prior art (U.S. Patent No. 3,849,550 (“‘550 patent”)) results in…distinguished the patents-in-suit from an earlier European patent application, EPA 0 383 620 (“‘620 patent application…filed suit for patent infringement and declaratory judgment, with respect to the same patents, against Defendants External link to document
2008-12-08 20 Answer to Counterclaim Declaratory Judgment of Noninfringement of U.S. Patent No. 5,981,589) 44. Plaintiffs reallege and incorporate… Invalidity and Unenforceability of U.S. Patent No. 5,981,589) 54. Plaintiffs reallege and incorporate…(5) Plaintiffs admit that U.S. Patent No. 3,849,550 (“the ’5 50 patent”) lists Dvora Teitelbaum, Ruth …co-inventors, that on its face the ’550 patent issued from U.S. Patent Application No. 240,244 (“the ’244 …’161, ’098, ’539, ’430 and ’847 patents claim priority to U.S. Patent Application No. 08/248,037, now External link to document
2010-12-03 206 Declaration of Karen Hagberg the prosecution history of United States patent 6,342,476. 5. Attached hereto as Exhibit…copy of the prosecution history of United States patent 5,800,808. …copy of the prosecution history of United States patent 6,048,898. 4. Attached hereto as Exhibit…copy of the prosecution history of United States patent 6,362,161. 6. Attached hereto as Exhibit…2008 24 July 2012 1:08-cv-07611 830 Patent Defendant District Court, S.D External link to document
2011-11-15 239 Proposed Findings of Fact .S. Patent No. 5,800,808: Claim 1 U.S. Patent No. 5,981,589: Claim 1 U.S. Patent No.…issued as U.S. Patent No. 5,800,808 (“the ’808 patent”) and No. 5,981,589 (“the ’589 patent”), respectively… ’898 Patent, Claims 1- 3 of the ’430 Patent, Claim 1 of the ’476 Patent, and Claim…claims 1-3 of the ’898 Patent, claims 1-3 of the ’430 Patent, claim 1 of the ’476 Patent, and claim 1 of the…inventors of the patents-in-suit. (PTX 26, ’550 patent, col. 1:3-8; PTX 1- 9.) The ’550 patent cites on its External link to document
2011-11-15 240 Response The patents-in-suit are U.S. Patent Nos. 5,981,589 (“the’589 Patent”), 6,054,430 (“the’430 Patent”), 6,342,476…TEV000310385-389; PTX 14 (File History of U.S. Patent No. 5,981,589 (“’589 File History”)) at TEV000309018-21…847 patent. Claims 1-3 of the ’898 patent; claims 1-3 of the ’430 patent; claim 1 of the ’476 patent and…multiple patents and patent applications, including both the ’550 patent and the Gad patents. Teva claims…808 patent, claim 1 of the ’589 patent, claim 1 of the ’847 patent, claims 1-3 of the ’430 patent, claim External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Moodys
Medtronic
Dow
Baxter
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.